Acute Myeloid Leukemia (AML) is a devastating disease with poor overall survival. Access to Precision Medicine (PM) is revolutionizing AML care and driving an increase in the use of Next Generation Sequencing (NGS) to determine the genomic profile of patients with AML. Advanced analysis into the interplay between mutational status for multiple genes is granting access to new targeted and PM treatment options with improved outcomes. Multiple hurdles in the clinical diagnostic testing ecosystem prevent patients from benefiting from many of these advances. Harnessing the power of patient data on an interactive network platform that navigates the patient journey in an efficient manner, and in collaboration with multiple stakeholders (e.g., pharmaceutical companies, labs, regulators), may eliminate those hurdles.
Diaceutics, a precision diagnostics commercialization company for the global pharmaceutical industry, has amassed more than 227 million real-world patient records from 35 countries in its proprietary global Diagnostic Index database. By merging these patient data into its soon-to-be-launched interactive network platform called DXRX, Diaceutics offers a solution to the broken clinical diagnostic testing ecosystem reducing patient leakage due to suboptimal testing.
Watch the overview: